文献速递脑血管病

自发性脑出血后重启抗血小板治疗:功能结局

Restarting antiplatelet therapy after spontaneous intracerebral hemorrhage: Functional outcomes.
PubMed 文献 · Neurology · 2018-05-30

在ERICH研究中,比较脑出血后重启与不重启抗血小板治疗(APT)患者的功能结局和健康相关生活质量。重启APT与较低的良好功能结局率和较低Barthel指数相关;1:1匹配后两组主要结局无差异。结论认为轻中度脑出血患者急性住院后重启APT与90天功能结局或健康相关生活质量变差无关。

要点

  • 重启APT队列127例与不重启队列732例相比,良好功能结局率36.5% vs 40.8%(p=0.021),Barthel指数较低(p=0.041)。
  • 1:1匹配后各107例,重启 vs 不重启APT主要结局35.5% vs 43.9%(p=0.105),无差异。
  • 轻中度脑出血患者急性住院后重启APT与90天功能结局或健康相关生活质量变差无关。

核心结论

  • 轻中度脑出血患者急性住院后重启APT与90天功能结局或健康相关生活质量变差无关。
  • 对于有明显心血管危险因素的脑出血患者,是否重启APT仍由治疗医生决定。

研究设计与样本

  • ERICH(脑出血的种族/民族变异)研究,纳入18岁及以上、脑出血前正在使用APT且出院时存活的患者。
  • 根据出院后是否重启APT将患者二分,重启APT队列127例,不重启APT队列732例。
  • 随后按1:1匹配,匹配后两组各107例。

主要发现

  • 重启APT与较低的良好功能结局率相关(36.5% vs 40.8%;p=0.021),且90天Barthel指数较低(p=0.041)。
  • 1:1匹配后,重启 vs 不重启APT的主要结局无差异(35.5% vs 43.9%;p=0.105)。
  • 匹配后两组的次要结局亦无差异。

关键数值与推荐

  • 主要结局为90天改良Rankin量表评分0-2分。
  • 次要结局包括90天极好结局(改良Rankin量表评分0-1分)、死亡率、Barthel指数和健康状况(EuroQol-5维度[EQ-5D]及EQ-5D视觉模拟量表评分)。

临床怎么用

  • 对于有明显心血管危险因素的脑出血患者,是否重启APT仍由治疗医生决定。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the functional outcomes and health-related quality of life metrics of restarting vs not restarting antiplatelet therapy (APT) in patients presenting with intracerebral hemorrhage (ICH) in the ERICH (Ethnic/Racial Variations of Intracerebral Hemorrhage) study. METHODS: Adult patients aged 18 years and older who were on APT before ICH and were alive at hospital discharge were included. Patients were dichotomized based on whether or not APT was restarted after hospital discharge. The primary outcome was a modified Rankin Scale score of 0-2 at 90 days. Secondary outcomes were excellent outcome (modified Rankin Scale score 0-1), mortality, Barthel Index, and health status (EuroQol-5 dimensions [EQ-5D] and EQ-5D visual analog scale scores) at 90 days. RESULTS: The APT and no APT cohorts comprised 127 and 732 patients, respectively. Restarting APT was associated with lower rates of good functional outcome (36.5% vs 40.8%; p = 0.021) and lower Barthel Index scores at 90 days (p = 0.041). The 2 cohorts were then matched in a 1:1 ratio, and the matched cohorts each comprised 107 patients. No difference in primary outcome was observed between restarting vs not restarting APT (35.5% vs 43.9%; p = 0.105). There were also no differences between the secondary outcomes of the 2 cohorts. CONCLUSION: Restarting APT in patients with ICH of mild to moderate severity after acute hospitalization is not associated with worse functional outcomes or health-related quality of life at 90 days. In patients with significant cardiovascular risk factors who experience an ICH, restarting APT remains the decision of the treating practitioner.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Chen CJ, Ding D, Buell TJ, et al. Restarting antiplatelet therapy after spontaneous intracerebral hemorrhage: Functional outcomes. Neurology. 2018. PMID: 29848784. doi:10.1212/WNL.0000000000005742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。